Mitomycin C, BCG Comparable For High-Risk Bladder Cancer
A 10-year follow-up study of patients with high-risk bladder cancer shows that mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) have similar effects on disease progression, need for subsequent treatment, and survival.
A Norwegian study included 261 patients with high-risk but not muscle-invasive bladder cancer. They were randomized to receive either 40 mg of MMC or 120 mg of BCG given weekly for six weeks, then monthly for up to a year, and finally every third month for another year. Of the 261 patients, 250 were evaluable (125 in each group).
The median follow-up for survivors was 123 months. The disease progressed in 58 patients (23%): 34 in the MMC group (27%) and 24 in the BCG group (19%).
Subsequent treatment was given to 47 patients: 26 in the MMC group and 21 in the BCG group. Of the 140 patients who died, 72 were in the MMC group and 68 were in the BCG group. None of the differences between the groups were statistically significant.